WO2017131034A1 - Préparation pharmaceutique pour absorption transdermique - Google Patents

Préparation pharmaceutique pour absorption transdermique Download PDF

Info

Publication number
WO2017131034A1
WO2017131034A1 PCT/JP2017/002553 JP2017002553W WO2017131034A1 WO 2017131034 A1 WO2017131034 A1 WO 2017131034A1 JP 2017002553 W JP2017002553 W JP 2017002553W WO 2017131034 A1 WO2017131034 A1 WO 2017131034A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug reservoir
drug
mass
layer
reservoir layer
Prior art date
Application number
PCT/JP2017/002553
Other languages
English (en)
Japanese (ja)
Inventor
智史 天野
昭雄 竹内
小林　弘明
隆夫 黒川
真美子 山▲崎▼
栗林　満
啓太 本村
Original Assignee
久光製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 久光製薬株式会社 filed Critical 久光製薬株式会社
Priority to JP2017564310A priority Critical patent/JP6556873B2/ja
Publication of WO2017131034A1 publication Critical patent/WO2017131034A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Definitions

  • the present invention relates to a percutaneous absorption preparation containing a drug and a silicone adhesive.
  • Patent Document 1 discloses the structure of a transdermally absorbable preparation comprising a drug reservoir layer, a drug permeation layer and a support. This transdermally absorbable preparation can absorb the drug percutaneously through the drug permeation layer without bringing the drug reservoir layer into direct contact with the skin.
  • the percutaneous absorption preparation such as the structure described in Patent Document 1 has a structure in which the drug reservoir layer is not in direct contact with the skin, the drug released from the percutaneous absorption preparation when applied to the skin for a long period of time. May cause skin irritation.
  • an object of the present invention is to provide a percutaneous absorption preparation in which drug-induced skin irritation caused by long-term application is reduced.
  • the inventors have made the pressure-sensitive adhesive layer contain a silicone pressure-sensitive adhesive containing polyorganosiloxane in an amount of 20% by mass or more with respect to the total mass of the pressure-sensitive adhesive layer, so the, 20g / m 2 ⁇ 24hr or more, by a 314g / m 2 ⁇ 24hr within the range, it is possible to make the percutaneous absorption preparation having a suitable sustained release and skin permeation persistence of drug, As a result, the inventors have found that the above problems can be solved.
  • the transdermally absorbable preparation has first and second main surfaces, and is provided on a drug reservoir layer containing a drug and on the first main surface side of the drug reservoir layer.
  • a transdermal absorption preparation comprising a pressure-sensitive adhesive layer containing a silicone pressure-sensitive adhesive containing polyorganosiloxane, and a support formed so as to cover a side surface of the drug reservoir layer and the second main surface.
  • the content of the silicone pressure-sensitive adhesive is 20% by mass or more with respect to the total mass of the pressure-sensitive adhesive layer, and the moisture permeability of the transdermal absorption preparation as a whole is 20 g / m 2 ⁇ 24 hr or more, 314 g / m 2.
  • Provide a transdermally absorbable preparation that is 24 hr or less.
  • the pressure-sensitive adhesive layer may further contain a pressure-sensitive adhesive base containing one or more compounds selected from the group consisting of a styrene-isoprene-styrene block copolymer (SIS), a tackifier resin, and a plasticizer. You may contain 80 mass% or less of the said adhesive base with respect to the total mass of an adhesive layer.
  • the drug reservoir layer may contain ethyl cellulose. The content of ethyl cellulose in the drug reservoir layer may be 40 to 99% by mass with respect to the total mass of the drug reservoir layer.
  • the drug reservoir layer may contain an acrylic base. The content of the acrylic base in the drug reservoir layer may be 40 to 99% by mass with respect to the total mass of the drug reservoir layer.
  • the support may contain a polyethylene terephthalate (PET) knitted fabric or an ethylene vinyl acetate copolymer film.
  • PET polyethylene terephthalate
  • the transdermally absorbable preparation according to the present invention has appropriate sustained release of the drug and long-term skin permeation, and can reduce drug-derived skin irritation caused by long-term application.
  • One embodiment of the present invention has first and second main surfaces, a drug reservoir layer containing a drug, and provided on the first main surface side of the drug reservoir layer, and includes polyorganosiloxane
  • a percutaneously absorbable preparation comprising a pressure-sensitive adhesive layer containing a silicone pressure-sensitive adhesive, and a support formed to cover the side surface of the drug reservoir layer and the second main surface. content, the is 20 mass% or more relative to the total weight of the adhesive layer, the moisture permeability of the whole percutaneous absorption preparation is 20g / m 2 ⁇ 24hr or more, or less 314g / m 2 ⁇ 24hr, through It is a skin-absorbing preparation.
  • the moisture permeability of the whole percutaneous absorption preparation is 20g / m 2 ⁇ 24hr or more, or less 314g / m 2 ⁇ 24hr.
  • the lower limit of moisture permeability as the whole transdermally absorbable preparation is not particularly limited, and may be 25, 30, 35, 40, or 100 g / m 2 ⁇ 24 hr.
  • the upper limit value of moisture permeability as the whole transdermally absorbable preparation is not particularly limited, and may be 150, 200, 250, or 300 g / m 2 ⁇ 24 hr.
  • the drug reservoir layer is a layer containing a drug to be administered transdermally.
  • the area of the drug reservoir layer can be arbitrarily set in consideration of the drug amount, the application time, etc., but is, for example, in the range of 3 to 150 cm 2 , preferably in the range of 10 to 100 cm 2 , and in the range of 10 to 50 cm 2 . A range is more preferred.
  • the thickness of the drug reservoir layer is not particularly limited, but is preferably 25 to 1000 ⁇ m from the viewpoint that it can contain an amount of drug capable of exerting a sufficient therapeutic effect over the application period of the preparation, ease of production, strength of the preparation, etc. 50 to 500 ⁇ m is more preferable, and 75 to 250 ⁇ m is more preferable.
  • the drug is not particularly limited as long as it is transdermally administrable, but the more easily the drug causes skin irritation, the more easily the skin irritation reducing effect of the present invention is exhibited.
  • Examples of drugs that are relatively susceptible to skin irritation include oxybutynin, asenapine, bisoprolol, risperidone, nicotine, and citalopram.
  • non-steroidal anti-inflammatory drugs such as indomethacin, ketoprofen, methyl salicylate, glycol salicylate, diclofenac sodium, flurbiprofen, felbinac, meloxicam and loxoprofen sodium, estradiol, norethisterone
  • hormonal drugs such as estriol, antihistamines such as ketotifen, anti-Alzheimer drugs such as memantine, rivastigmine, donepezil, galantamine, sertraline, fluoxetine, paroxetine, antidepressants such as fluvoxamine, gastric ulcer drugs such as teprone, tolterodine, And overactive bladder drugs such as solifenacin, bronchodilators such as tulobuterol, Parkinson's disease drugs such as rotigotine, and metoprolol Antihypertensive drugs, and the like.
  • the drug may be selected from the group consisting of, for example, oxybutynin, asenapine, bisoprolol, citalopram, diclofenac sodium, memantine, rivastigmine, donepezil, galantamine, fluoxetine, paroxetine, tolterodine, and rotigotine.
  • the drug contained in the drug reservoir can be contained in the drug reservoir in a dissolved state, a saturated state, a supersaturated crystal state, or a dispersed state.
  • the lower limit of the content of the drug contained in the drug reservoir layer is not particularly limited, and may be 1, 5, 10, 15, 20, 30, or 40% by mass with respect to the total mass of the drug reservoir layer. When it is at least the above lower limit, sufficient skin permeability of the drug is easily obtained.
  • the upper limit of the content of the drug contained in the drug reservoir layer is not particularly limited, and may be 50, 60, 70, 80, or 85 mass% with respect to the total mass of the drug reservoir layer. When the amount is not more than the above upper limit value, sufficient strength for maintaining the shape of the drug reservoir layer is easily secured.
  • the content of the drug contained in the drug reservoir layer may be, for example, 1 to 90% by mass and 15 to 85% by mass with respect to the total mass of the drug reservoir layer.
  • the drug reservoir layer may contain ethyl cellulose. Since the drug reservoir contains ethyl cellulose, the drug reservoir maintains cohesiveness even when exposed to perspiration at the skin application site, environmental moisture, etc., and can reduce skin irritation due to swelling and destruction. .
  • the lower limit of the content of ethylcellulose contained in the drug reservoir layer is not particularly limited, and may be 20, 25, 30, 35, 40, or 50 mass% with respect to the total mass of the drug reservoir layer. It is easy to maintain the cohesiveness of a drug reservoir layer as it is above the lower limit.
  • the upper limit value of the content of ethyl cellulose contained in the drug reservoir layer is not particularly limited, and may be 70, 80, 90, 95, or 99 mass% with respect to the total mass of the drug reservoir layer.
  • the content of ethyl cellulose contained in the drug reservoir layer may be, for example, 40 to 99% by mass with respect to the total mass of the drug reservoir layer.
  • the drug reservoir may contain an acrylic base. Because the drug reservoir contains an acrylic base, the drug reservoir maintains cohesiveness and reduces skin irritation due to swelling and destruction even when exposed to sweat at the skin application site and moisture in the environment. Can do.
  • the lower limit value of the content of the acrylic base contained in the drug reservoir layer is not particularly limited, and may be 20, 25, 30, 35, 40, or 50 mass% with respect to the total mass of the drug reservoir layer. It is easy to maintain the cohesiveness of a drug reservoir layer as it is above the lower limit.
  • the upper limit of the content of the acrylic base contained in the drug reservoir layer is not particularly limited, and may be 70, 80, 90, 95, or 99 mass% with respect to the total mass of the drug reservoir layer.
  • the content of the acrylic base contained in the drug reservoir layer may be, for example, 40 to 99% by mass with respect to the total mass of the drug reservoir layer.
  • (meth) acrylic acid alkyl ester having an alkyl group having 4 to 18 carbon atoms, or the above (meth) acrylic acid alkyl ester and other A copolymer with a functional monomer is preferably used.
  • (meth) acryl means acryl or methacryl.
  • an acrylate copolymer is preferable.
  • the acrylate copolymer may be selected from the group consisting of an acrylate copolymer having no functional group, an acrylate copolymer having a hydroxy group, an acrylate copolymer having a carboxy group, and combinations thereof.
  • Examples of the acrylate copolymer having no functional group include Duro-tak (registered trademark, Henkel Corporation) 87-9900, Duro-tak (registered trademark) 87-9301, GELVA (registered trademark) GMS 3083, and the like. It is done.
  • Examples of the acrylate copolymer having a hydroxy group include hydroxyalkyl acrylates such as 2-hydroxyethyl acrylate. The hydroxyalkyl acrylate may be further substituted with a halogen atom, an alkyl group, an alkenyl group, an alkynyl group or the like.
  • Examples of the acrylate copolymer having a hydroxy group include Duro-tak (registered trademark) 87-2516, GELVA (registered trademark) GMS 788, GELVA (registered trademark) GMS 737, and the like.
  • Examples of the acrylate copolymer having a carboxy group include acrylic acid-containing acrylate copolymers.
  • the monomer component copolymerized with acrylic acid is not particularly limited as long as it can be copolymerized with acrylic acid. Examples thereof include acrylic acid esters such as methyl acrylate and 2-ethylhexyl acrylate; Examples include acrylic acid amides such as acid morpholine amide; vinyl acetate; vinyl alcohol; styrene.
  • the monomer component copolymerized with acrylic acid may be one kind alone, or two or more kinds.
  • Examples of the acrylate copolymer having a carboxy group include Duro-tak (registered trademark) 87-2194, Duro-tak (registered trademark) 87-2852, GELVA (registered trademark) GMS 753, and the like.
  • the drug reservoir layer may contain components other than the drug and ethyl cellulose as long as the coagulability of the drug reservoir layer can be maintained.
  • other components include, but are not limited to, drug stabilizers, plasticizers, solubilizers, transdermal absorption enhancers, and fats and oils.
  • the stabilizer is not particularly limited as long as it is a compound that has been confirmed to have a stabilizing action in a transdermal absorption preparation, and examples thereof include tocopherols, ascorbic acids, dibutylhydroxytoluene, sodium hydrogen sulfite, and ethylenediaminetetraacetate. It is done.
  • the plasticizer is not particularly limited as long as it is a compound in which a plasticizing action is recognized in the transdermal preparation, and examples thereof include liquid paraffin, liquid polybutene, liquid polyisoprene, and esterified oils.
  • the solubilizing agent is not particularly limited as long as it is a compound having a dissolving action on a drug
  • the percutaneous absorption enhancer is not particularly limited as long as it is a compound having an absorption promoting action in a transdermal absorption preparation.
  • the solubilizer and absorption promoter include fatty acids having 6 to 20 carbon chains, aliphatic alcohols, fatty acid esters, fatty acid amides, fatty acid ethers, aromatic organic acids, aromatic alcohols, and aromatic organic acids.
  • Esters aromatic organic acid ethers (which may be saturated or unsaturated, and may be cyclic, linear or branched), lactic acid esters, acetic acid esters, monoterpene compounds, sesquiterpenes Compounds, Azone, Azone derivatives, Pyrothiodecane, Glycerin fatty acid esters, Propylene glycol fatty acid esters, Sorbitan fatty acid esters (Span), Polysorbate (Tween), Polyethylene glycol fatty acid esters, Polyoxyethylene cured Castor oil (HCO), polyoxy Chi alkylene alkyl ethers, sucrose fatty acid esters and vegetable oil, and the like.
  • lauryl alcohol myristyl alcohol, oleyl alcohol, isostearyl alcohol, diethyl sebacate, glycerol monocaprate, glycerol monolaurate, glycerol monooleate, sorbitan monolaurate, propylene glycol monolaurate, polyoxyethylene
  • lauryl ether pyrothiodecane, and isopropyl myristate.
  • the pressure-sensitive adhesive layer is a layer that is provided on the first main surface side of the drug reservoir layer that is in contact with the skin, and serves to prevent the drug reservoir layer from directly contacting the skin.
  • the area of the pressure-sensitive adhesive layer is not particularly limited as long as it is equal to or larger than the area of the drug reservoir layer, but is preferably wider than the drug reservoir layer in order to securely fix the support covering the drug reservoir layer.
  • the thickness of an adhesive layer is not specifically limited, It can set arbitrarily.
  • the pressure-sensitive adhesive layer contains a silicone pressure-sensitive adhesive containing polyorganosiloxane.
  • the pressure-sensitive adhesive layer contains a silicone pressure-sensitive adhesive containing polyorganosiloxane, the moisture permeability of the transdermally absorbable preparation is increased.
  • the polyorganosiloxane commercially available products such as BIO-PSA 7-4202 and BIO-PSA 7-4302 manufactured by Dow Corning can be used.
  • the lower limit value of the polyorganosiloxane content in the silicone pressure-sensitive adhesive is not particularly limited, and may be 40, 50, 60, 70, 80, or 90% by mass.
  • the upper limit of the content of polyorganosiloxane in the silicone pressure-sensitive adhesive is not particularly limited, and may be 80, 90, 95 or 100% by mass.
  • Content of a silicone adhesive is 20 mass% or more with respect to the total mass of an adhesive layer.
  • the lower limit of the content of the silicone pressure-sensitive adhesive may be 30, 35, or 40% by mass with respect to the total mass of the pressure-sensitive adhesive layer.
  • the upper limit of content of a silicone adhesive is not specifically limited, It may be 60, 70, 80, 90 or 100 mass% with respect to the total mass of an adhesive layer.
  • the pressure-sensitive adhesive layer may further contain a pressure-sensitive adhesive base containing one or more compounds selected from the group consisting of a styrene-isoprene-styrene block copolymer, a tackifying resin, and a plasticizer in addition to the silicone pressure-sensitive adhesive. More preferably, it further contains an adhesive base containing two or more compounds selected from the group consisting of a styrene-isoprene-styrene block copolymer, a tackifier resin and a plasticizer, and a styrene-isoprene-styrene block. It is further preferable to further contain an adhesive base containing a copolymer, a tackifying resin and a plasticizer. By further containing the above adhesive base, the permeation persistence of the transdermally absorbable preparation can be enhanced.
  • the lower limit of the content of the styrene-isoprene-styrene block copolymer in the adhesive base is not particularly limited, and may be 1, 5, 10 or 20% by mass with respect to the total mass of the adhesive base.
  • the upper limit of the content of the styrene-isoprene-styrene block copolymer in the adhesive base is not particularly limited, and is 60, 70, 80, 90, or 95% by mass with respect to the total mass of the adhesive base. It's okay.
  • the tackifying resin is not particularly limited as long as it is a compound having an effect of improving the adhesive strength.
  • alicyclic saturated hydrocarbon resin for example, Alcon P-100 of Arakawa Chemical Industries
  • rosin derivative for example, rosin
  • Rosin glycerin ester for example, hydrogenated rosin and hydrogenated rosin glycerin ester
  • terpene resin for example, Clearon P-125 of Yashara Chemical
  • aliphatic hydrocarbon resin for example, Quinton B170 of Nippon Zeon
  • maleic resin etc.
  • the lower limit value of the content of the tackifying resin in the adhesive base is not particularly limited, and may be 5, 10, 20, 30, or 40% by mass with respect to the total mass of the adhesive base.
  • the upper limit of content of the tackifying resin in the said adhesive base is not specifically limited, It may be 60, 70, 80, 90, or 95 mass% with respect to the total mass of an adhesive base.
  • the plasticizer is as described above.
  • the lower limit of content of the plasticizer in the said adhesive base is not specifically limited, It may be 1, 5, 10 or 20 mass% with respect to the total mass of the said adhesive base.
  • the upper limit of content of the plasticizer in the said adhesive base is not specifically limited, It may be 60, 70, 80, 90, or 95 mass% with respect to the total mass of an adhesive base.
  • the lower limit of content of the said adhesive base is not specifically limited, It may be 5, 10, 20, 30 or 40 mass% with respect to the total mass of an adhesive layer.
  • the upper limit of content of the said adhesive base is not specifically limited, It may be 60, 70, 80, 90, or 95 mass% with respect to the total mass of an adhesive layer.
  • the ratio of the content of the silicone pressure-sensitive adhesive and the pressure-sensitive adhesive base in the pressure-sensitive adhesive layer may be 1: 4 to 7: 3, or 3: 7 to 7: 3. . When the ratio is in the above range, the skin permeation persistence tends to be enhanced while maintaining good moisture permeability of the transdermally absorbable preparation.
  • the pressure-sensitive adhesive layer may further contain a (meth) acrylic acid ester copolymer.
  • the (meth) acrylic acid ester copolymer include C4-C20 alkyl ester of (meth) acrylic acid and (meth) acrylic acid hydroxy C4-C20 alkyl ester as main monomers.
  • Copolymerized monomers of (meth) acrylic acid ester copolymers include C4 to C20 alkyl esters of (meth) acrylic acid, (meth) acrylic acid hydroxy C4 to C20 alkyl esters, (meth) acrylic acid, vinyl acetate and vinyl. Examples include pyrrolidone and the like.
  • the pressure-sensitive adhesive layer may contain components other than the pressure-sensitive adhesive and the pressure-sensitive adhesive base.
  • the other components are not particularly limited as long as they are generally used for transdermally absorbable preparations, and examples thereof include stabilizers.
  • the support is a layer that holds the drug reservoir layer.
  • the area of a support body is not specifically limited, It can set arbitrarily.
  • the thickness of the support is not particularly limited, but is, for example, 1 to 3000 ⁇ m, preferably 1 to 1000 ⁇ m, more preferably 50 to 500 ⁇ m, and further preferably 100 to 250 ⁇ m.
  • the support is made of a sheet having a property that does not swell due to migration of a drug or the like in the drug reservoir layer.
  • the material for the support include polyester (such as PET), polyolefin (such as polyethylene and polypropylene), and polyurethane.
  • the properties of the support include films, nonwoven fabrics, woven fabrics, knitted fabrics, and porous sheets.
  • Examples of the water repellent treatment include silicone water repellent, fluororesin water repellent, paraffin wax water repellent, zirconium compound water repellent, ethylene urea water repellent, methylolamide water repellent and aliphatic. Treatment with a water repellent or the like can be mentioned.
  • a laminate film of PET film and PET nonwoven fabric hereinafter referred to as PET / nonwoven fabric laminate film
  • PET / nonwoven fabric laminate film a laminate film of PET film and PET nonwoven fabric
  • a polyurethane film a polyurethane film
  • an ethylene vinyl acetate copolymer film are preferable
  • a water-repellent treated PET knitted fabric Is more preferable.
  • the support may be selected, for example, from the group consisting of a water-repellent treated PET knitted fabric, an ethylene vinyl acetate copolymer film, a PET / nonwoven fabric laminate film, a polyurethane nonwoven fabric, a polyurethane film, and a PET film. Further, from the viewpoint of increasing the moisture permeability of the transdermally absorbable preparation, the support is selected from the group consisting of a water-repellent treated PET knitted fabric, an ethylene vinyl acetate copolymer film, a polyurethane nonwoven fabric, and a polyurethane film. It is preferable.
  • the support is more preferably a PET knitted fabric or an ethylene vinyl acetate copolymer film subjected to a water repellent treatment.
  • the back-through of the drug refers to a phenomenon in which the drug escapes from the support side due to moisture brought from the external environment.
  • the transdermally absorbable preparation of the present invention may be further covered with a cover material, or the cover material may be further laminated.
  • the cover material is composed of a support and an adhesive layer laminated on one side.
  • Cover materials include those that cover the transdermally absorbable preparation of the present invention and are fixed to the skin, and those that are further laminated on the transdermally absorbable preparation.
  • the cover material can be used, for example, to maintain the state of the percutaneously absorbable preparation during the administration period of the drug and to protect the percutaneously absorbable preparation from moisture (such as a shower) brought from the external environment.
  • the support of the cover material is preferably provided with appropriate strength, moisture permeability, water resistance, and the like, and is preferably selected from polyester (PET, etc.), polyolefin (polyethylene, polypropylene, etc.) and polyurethane.
  • Examples of the properties of the support of the cover material include films (preferably urethane films), non-woven fabrics, woven fabrics, knitted fabrics, porous sheets, and the like, but sweat generated when a percutaneous absorption preparation is applied to the skin. From the point of promoting the volatilization of moisture such as, it is preferably a cloth shape, more preferably a knitted fabric.
  • the support When the support is in the form of a cloth, it may be subjected to water repellent treatment in order to improve its waterproofness.
  • Examples of the water repellent treatment include silicone water repellent, fluororesin water repellent, paraffin wax water repellent, zirconium compound water repellent, ethylene urea water repellent, methylolamide water repellent and aliphatic. Treatment with a water repellent or the like can be mentioned.
  • the adhesive layer of the cover material covers the percutaneously absorbable preparation and is fixed to the skin, it has an adhesive property for fixing the percutaneously absorbable preparation to the skin and is further laminated on the percutaneously absorbable preparation. In this case, it has adhesiveness for adhering to the transdermally absorbable preparation. It is preferable that the cover material has further excellent moisture permeability.
  • Examples of the adhesive base contained in the adhesive layer of the cover material include an acrylic adhesive, a silicone adhesive, and a rubber adhesive.
  • an acrylic adhesive what contains a (meth) acrylic acid ester copolymer is mentioned, for example.
  • Examples of the (meth) acrylic acid ester copolymer include C4-C20 alkyl ester of (meth) acrylic acid and (meth) acrylic acid hydroxy C4-C20 alkyl ester as main monomers.
  • Copolymerized monomers of (meth) acrylic acid ester copolymers include C4 to C20 alkyl esters of (meth) acrylic acid, (meth) acrylic acid hydroxy C4 to C20 alkyl esters, (meth) acrylic acid, vinyl acetate and vinyl. Examples include pyrrolidone and the like.
  • silicone pressure-sensitive adhesive examples include polydimethylsiloxane.
  • rubber adhesive examples include polyisobutylene (PIB), polyisoprene, and styrene-isoprene-styrene block copolymer (SIS).
  • the pressure-sensitive adhesive layer of the cover material may contain components other than the pressure-sensitive adhesive.
  • the other components are not particularly limited as long as they are generally used for transdermally absorbable preparations, and examples thereof include tackifier resins, plasticizers, and stabilizers.
  • the cover material is provided separately from the percutaneous absorption preparation, may be used in combination with the application of the percutaneous absorption preparation, or may be provided in a form bonded in advance to the percutaneous absorption preparation.
  • the pressure-sensitive adhesive layer of the transdermally absorbable preparation of the present invention or the pressure-sensitive adhesive layer of the cover material may be covered with a layer for protecting the pressure-sensitive adhesive layer until application to the skin, for example, a layer comprising a release liner. .
  • Release liners include, for example, films such as polyester (such as PET), polyvinyl chloride, polyvinylidene chloride, nylon and polyolefin (such as polyethylene and polypropylene), paper such as fine paper and glassine paper, fine paper or glassine paper, and polyolefin Laminating film or the like.
  • the release liner can be subjected to a wrinkle release treatment by applying a silicone resin, a fluororesin or the like to the surface in contact with the pressure-sensitive adhesive layer.
  • the release liner may be formed from a plurality of pieces.
  • the release liner has a size that can cover at least the entire pressure-sensitive adhesive layer of the transdermal absorption preparation or the pressure-sensitive adhesive layer of the cover material, and may extend outward from each pressure-sensitive adhesive layer.
  • Examples of the basic production method of the transdermally absorbable preparation of the present invention include the following methods.
  • a drug reservoir is obtained by cutting.
  • the drug reservoir layer is heated and softened and bonded to the support.
  • a drug reservoir layer is laminated on the pressure-sensitive adhesive layer, and cut into an appropriate shape to obtain a transdermally absorbable preparation.
  • the sheet serving as the cover material can be obtained by forming a pressure-sensitive adhesive layer on a release liner by a conventional method, laminating a support on the pressure-sensitive adhesive layer, and cutting it into an appropriate shape.
  • the release liner When covering the percutaneously absorbable preparation with a cover material, the release liner is peeled off from the cover material sheet, and the support layer of the percutaneously absorbable preparation is joined to the adhesive surface of the adhesive layer of the exposed cover material sheet, Cut into an appropriate shape if necessary. Furthermore, when the adhesive layer of the transdermal absorption preparation is coated with a release liner, the release liner attached to the transdermal absorption preparation is peeled and removed as necessary, and the adhesive surface of the cover material sheet is instead removed with the release liner. After covering the side to form a sheet, it is cut into an appropriate shape.
  • the coating liquid was applied onto the release liner, and the solvent was removed by drying to obtain a pressure-sensitive adhesive layer having a thickness of 75 g / m 2 .
  • the drug reservoir layer is bonded on the adhesive layer, the release liner of the drug reservoir layer is peeled and removed, and a support (water-repellent PET knitted fabric) is laminated on the exposed surface, with the drug reservoir layer approximately in the center. It was cut in (38cm 2), whereby a transdermal absorption preparation was obtained.
  • Moisture permeability test method The moisture permeability of the transdermally absorbable preparation is determined according to the moisture permeability test method (cup method) of the moisture-proof packaging material defined in JIS Z 0208: 1976. Relative humidity: Moisture permeation rate (MVTR) g / m 2 ⁇ 24 hr at 90 ⁇ 2% was measured.
  • MVTR Moisture permeation rate
  • moisture permeability of 40g / m 2 ⁇ 24hr or more moisture permeability is high, irritation of the skin is almost no
  • moisture permeability of 20g / m 2 ⁇ 24hr or more ⁇ 40g / m 2 ⁇ 24hr Less than moisture permeability is slightly high and skin irritation hardly occurs
  • the amount of drug permeated at each time was calculated from the measured concentration value, and the skin permeation rate ( ⁇ g / cm 2 / hr) of the drug at each time was determined. Further, as an index representing the permeation persistence of the drug, the skin permeation speed J last after 168 hours was divided by the maximum skin speed J max to calculate a J last / J max value. A large J last / J max value means that the drug permeation persistence is high.
  • J last / J max value is 0.60 or more ⁇ : J last / J max value is 0.30 or more and less than 0.60 ⁇ : J last / J max value is 0 Less than 30
  • the drug reservoir was obtained by weighing 40 mass% bisoprolol and 60 mass% ethyl cellulose and using the same method as described in Test 1.
  • the pressure-sensitive adhesive layer was obtained by weighing out 100% by mass of a silicone-based pressure-sensitive adhesive containing polyorganosiloxane and by the same method as described in Test 1.
  • the drug reservoir layer is bonded onto the adhesive layer, the release liner of the drug reservoir layer is peeled and removed, and the support of Table 3 is laminated on the exposed surface (Comparative Example 2 has no support laminate).
  • Moisture permeability test method The moisture permeability of the transdermally absorbable preparation is determined according to the moisture permeability test method (cup method) of the moisture-proof packaging material defined in JIS Z 0208: 1976. Relative humidity: Moisture permeation rate (MVTR) g / m 2 ⁇ 24 hr at 90 ⁇ 2% was measured.
  • MVTR Moisture permeation rate
  • a percutaneous absorption preparation using a PET knitted fabric (water repellent treatment), an ethylene vinyl acetate copolymer film, and a PET film as a support was found to have a high tendency to prevent the drug from falling through.
  • the drug reservoir layer is bonded onto the adhesive layer, the release liner of the drug reservoir layer is peeled and removed, a support (PET / nonwoven fabric laminate film) is laminated on the exposed surface, and the drug reservoir layer is approximately square ( 13.4 cm 2 ) to obtain a transdermal absorption preparation.

Abstract

L'invention concerne une préparation pharmaceutique pour absorption transdermique comprenant : une couche réservoir de médicament comprenant des première et seconde surfaces primaires et contenant un médicament ; une couche d'agent adhésif disposée sur la première surface primaire de la couche réservoir de médicament et contenant un agent adhésif de silicone qui comprend un polyorganosiloxane ; et un support formé de façon à recouvrir les surfaces latérales et la seconde surface primaire de la couche réservoir de médicament. La teneur en agent adhésif de silicium est supérieure ou égale à 20 % en masse par rapport à la masse totale de la couche adhésive, et la perméabilité à l'humidité de la préparation pharmaceutique pour absorption transdermique globale est comprise entre 20 g/m2·par 24 h et 314 g/m2·par 24 h.
PCT/JP2017/002553 2016-01-28 2017-01-25 Préparation pharmaceutique pour absorption transdermique WO2017131034A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2017564310A JP6556873B2 (ja) 2016-01-28 2017-01-25 経皮吸収製剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016014170 2016-01-28
JP2016-014170 2016-01-28

Publications (1)

Publication Number Publication Date
WO2017131034A1 true WO2017131034A1 (fr) 2017-08-03

Family

ID=59398365

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/002553 WO2017131034A1 (fr) 2016-01-28 2017-01-25 Préparation pharmaceutique pour absorption transdermique

Country Status (3)

Country Link
JP (1) JP6556873B2 (fr)
TW (1) TWI710381B (fr)
WO (1) WO2017131034A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020071205A1 (fr) * 2018-10-01 2020-04-09 久光製薬株式会社 Tampon adhésif contenant de l'asénapine
WO2020071207A1 (fr) * 2018-10-01 2020-04-09 久光製薬株式会社 Patch adhésif contenant de l'asénapine
US10898449B2 (en) 2016-12-20 2021-01-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US11648213B2 (en) 2018-06-20 2023-05-16 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112823793A (zh) * 2019-11-20 2021-05-21 成都康弘药业集团股份有限公司 一种含有多奈哌齐的透皮贴剂及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07157423A (ja) * 1993-12-06 1995-06-20 Sekisui Chem Co Ltd 経皮吸収貼付剤
JPH09124462A (ja) * 1995-11-01 1997-05-13 Nitto Denko Corp 貼付剤および貼付製剤
JPH11152224A (ja) * 1997-09-17 1999-06-08 Permatec Technol Ag 制御されかつ持続した経皮性投与用新規組成物
WO2007099966A1 (fr) * 2006-02-28 2007-09-07 Hisamitsu Pharmaceutical Co., Inc. Preparation pour absorption transdermique
WO2010095537A1 (fr) * 2009-02-18 2010-08-26 久光製薬株式会社 Préparation transdermique
JP2015508813A (ja) * 2012-02-28 2015-03-23 エスケー ケミカルズ カンパニー, リミテッドSk Chemicals Co., Ltd. ドネペジルを含有する経皮吸収製剤及びその製造方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07157423A (ja) * 1993-12-06 1995-06-20 Sekisui Chem Co Ltd 経皮吸収貼付剤
JPH09124462A (ja) * 1995-11-01 1997-05-13 Nitto Denko Corp 貼付剤および貼付製剤
JPH11152224A (ja) * 1997-09-17 1999-06-08 Permatec Technol Ag 制御されかつ持続した経皮性投与用新規組成物
WO2007099966A1 (fr) * 2006-02-28 2007-09-07 Hisamitsu Pharmaceutical Co., Inc. Preparation pour absorption transdermique
WO2010095537A1 (fr) * 2009-02-18 2010-08-26 久光製薬株式会社 Préparation transdermique
JP2015508813A (ja) * 2012-02-28 2015-03-23 エスケー ケミカルズ カンパニー, リミテッドSk Chemicals Co., Ltd. ドネペジルを含有する経皮吸収製剤及びその製造方法

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US10898449B2 (en) 2016-12-20 2021-01-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US10980753B2 (en) 2016-12-20 2021-04-20 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
US11648213B2 (en) 2018-06-20 2023-05-16 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
JPWO2020071207A1 (ja) * 2018-10-01 2021-09-02 久光製薬株式会社 アセナピン含有貼付剤
WO2020071205A1 (fr) * 2018-10-01 2020-04-09 久光製薬株式会社 Tampon adhésif contenant de l'asénapine
JPWO2020071205A1 (ja) * 2018-10-01 2021-09-02 久光製薬株式会社 アセナピン含有貼付剤
JP7152500B2 (ja) 2018-10-01 2022-10-12 久光製薬株式会社 アセナピン含有貼付剤
JP7152499B2 (ja) 2018-10-01 2022-10-12 久光製薬株式会社 アセナピン含有貼付剤
US11590106B2 (en) 2018-10-01 2023-02-28 Hisamitsu Pharmaceutical Co., Inc. Asenapine-containing adhesive patch
WO2020071207A1 (fr) * 2018-10-01 2020-04-09 久光製薬株式会社 Patch adhésif contenant de l'asénapine
US11850311B2 (en) 2018-10-01 2023-12-26 Hisamitsu Pharmaceutical Co., Inc. Asenapine-containing adhesive patch

Also Published As

Publication number Publication date
TW201726119A (zh) 2017-08-01
JP6556873B2 (ja) 2019-08-07
JPWO2017131034A1 (ja) 2018-09-06
TWI710381B (zh) 2020-11-21

Similar Documents

Publication Publication Date Title
JP6556873B2 (ja) 経皮吸収製剤
US6316022B1 (en) Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US8337884B2 (en) Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
JP3489831B2 (ja) 活性成分パッチ
EP1696013B1 (fr) Adhésif autocollant et pastille
CN107847487B (zh) 含有阿塞那平的贴剂
US20070264319A1 (en) Transdermal Antiemesis Delivery System, Method and Composition Therefor
JP5615697B2 (ja) β遮断剤の安定化組成物およびそれを用いた経皮吸収製剤
DK201600113U1 (da) Transdermalt, terapeutisk system til administration af rivastigmin
KR101853082B1 (ko) 활성제층 및 활성제 변환층을 포함하는 경피 조성물
JP3576608B2 (ja) 貼付剤および貼付製剤
JP5542791B2 (ja) 経皮吸収製剤
JP4824963B2 (ja) 貼付材及び貼付製剤
JP5870350B2 (ja) ビソプロロール経皮投与デバイス
CA2373171A1 (fr) Timbre extensible
KR20120137373A (ko) 프로필아미노인단 경피 조성물
WO2008050673A1 (fr) Timbre transdermique adhésif
JP6457486B2 (ja) 貼付製剤
JP4428903B2 (ja) 非吸蔵性裏打ち層を有する吸蔵性経皮治療系
JP2002537244A (ja) デオキシペガニン経皮治療系
WO2013047410A1 (fr) Timbre cutané adhésif à action longue pour le traitement de la maladie d'alzheimer et procédé pour le produire
US20050186262A1 (en) Transdermal delivery device for dihydropyridine type calcium antagonists
CN113382724A (zh) 贴剂
JP2971998B2 (ja) アクリル系粘着シートおよびこれを用いてなる粘着製剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17744264

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017564310

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17744264

Country of ref document: EP

Kind code of ref document: A1